TITLE:
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

CONDITION:
Major Depressive Disorder

INTERVENTION:
DVS-233 SR

SUMMARY:

      Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving
      DVS-233 SR versus subjects receiving placebo.

      Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the
      clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms
      (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to
      7) versus those subjects receiving placebo.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Outpatients

          -  Sexually active women participating in the study must use a medically acceptable form
             of contraception

          -  Subjects must have a primary diagnosis of major depressive disorder of 4 on Clinical
             Global Impressions-Severity scale (CGI-S)

        Exclusion Criteria:

          -  Treatment with DVS-233 SR at any time in the past

          -  Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within
             90 days of study day 1

          -  Known hypersensitivity to venlafaxine (IR or ER)
      
